Divin, Natalie;
Given, Joanne;
Tan, Joachim;
Astolfi, Gianni;
Ballardini, Elisa;
Barrachina Bonet, Laia;
Cavero, Clara;
... Loane, Maria; + view all
(2023)
Anti-asthmatic prescriptions in children with and without congenital anomalies: a population-based study.
BMJ Open
, 13
, Article e068885. 10.1136/bmjopen-2022-068885.
Preview |
Text
Tan_e068885.full.pdf Download (1MB) | Preview |
Abstract
Objectives To explore the risk of being prescribed/ dispensed medications for respiratory symptoms and breathing difficulties in children with and without congenital anomalies. Design A EUROlinkCAT population-based data linkage cohort study. Data on children with and without congenital anomalies were linked to prescription databases to identify children who did/did not receive antiasthmatic prescriptions. Data were analysed by age, European region, class of antiasthmatic, anomaly, sex, gestational age and birth cohort. Setting Children born 2000–2014 in six regions within five European countries. Participants 60 662 children with congenital anomalies and 1 722 912 reference children up to age 10 years. Primary outcome measure Relative risks (RR) of >1 antiasthmatic prescription in a year, identified using Anatomical Therapeutic Chemical classification codes beginning with R03. Results There were significant differences in the prescribing of antiasthmatics in the six regions. Children with congenital anomalies had a significantly higher risk of being prescribed antiasthmatics (RR 1.41, 95%CI 1.35 to 1.48) compared with reference children. The increased risk was consistent across all regions and all age groups. Children with congenital anomalies were more likely to be prescribed beta-2 agonists (RR 1.71, 95%CI 1.60 to 1.83) and inhaled corticosteroids (RR 1.74, 95%CI 1.61 to 1.87). Children with oesophageal atresia, genetic syndromes and chromosomal anomalies had over twice the risk of being prescribed antiasthmatics compared with reference children. Children with congenital anomalies born <32 weeks gestational age were over twice as likely to be prescribed antiasthmatics than those born at term (RR 2.20, 95%CI 2.10 to 2.30). Conclusion This study documents the additional burden of respiratory symptoms and breathing difficulties for children with congenital anomalies, particularly those born preterm, compared with children without congenital anomalies in the first 10 years of life. These findings are beneficial to clinicians and healthcare providers as they identify children with greater morbidity associated with respiratory symptoms, as indicated by antiasthmatic prescriptions.
| Type: | Article |
|---|---|
| Title: | Anti-asthmatic prescriptions in children with and without congenital anomalies: a population-based study |
| Open access status: | An open access version is available from UCL Discovery |
| DOI: | 10.1136/bmjopen-2022-068885 |
| Publisher version: | http://dx.doi.org/10.1136/bmjopen-2022-068885 |
| Language: | English |
| Additional information: | This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/. |
| UCL classification: | UCL UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Population Health Sciences > UCL GOS Institute of Child Health UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Population Health Sciences > UCL GOS Institute of Child Health > Population, Policy and Practice Dept |
| URI: | https://discovery.ucl.ac.uk/id/eprint/10177897 |
Archive Staff Only
 |
View Item |
